Dzhumashev D, Timpanaro A, Ali S, De Micheli AJ, Mamchaoui K, Cascone I, Rössler J, Bernasconi M (2022) Quantum dot-based screening identifies F3 peptide and reveals cell surface nucleolin as a therapeutic target for rhabdomyosarcoma. Cancers (Basel) 14(20):5048. doi: 10.3390/cancers14205048
Objective: To investigate targeted treatment options to improve overall survival rates and to limit long-term side effects of Rhabdomyosarcoma (RMS).
Summary: The authors tested 20 different tumor-targeting peptides for their ability to bind to two RMS cell lines, Rh30 and RD, using quantum dots Streptavidin and biotin-peptides conjugates as a model for nanoparticles. F3 peptide showed the strongest binding to all RMS cell lines tested, low binding to normal control myoblasts and fibroblasts, and efficient internalization into RMS cells demonstrated by the cytoplasmic delivery of the Saporin toxin. Results indicate that nucleolin-targeting by F3 peptide represents a potential therapeutic approach for RMS.
Usage: ZAP-conjugates were prepared for selected peptides. For conjugation, Streptavidin ZAP (IT-27) was incubated with biotinylated peptides at a ratio of 1:4. After 30 min of incubation at room temperature (25°C) with gentle agitation, ZAP-conjugates were added to 2500 fast-growing cells (RD) or 5’000 slower growing (Rh30, Rh4, TTC-442) cells seeded in a 96-well plate. Three-fold dilution of initial stock was performed to obtain the series of decreasing concentrations of ZAP-conjugates (54, 18, 6, 2, 0.67, 0.22, 0.074, 0.0247 nM). ZAP-conjugates were incubated for 48 h. Viability was measured using the MTT assay.
Related Products: Streptavidin-ZAP (Cat. #IT-27), Saporin (Cat. #PR-01)